
China lead poisoning: disease control agency, hospital faked results, probe finds
This comes nearly two weeks after police in Gansu's Tianshui city
detained eight people over their involvement in the poisoning that left more than 200 kindergarteners with high lead levels in their blood, in a case that shocked the nation.
According to an investigation report released by the provincial government on Sunday, the Gansu Provincial Centre for Disease Control and Prevention (CDC) and the Tianshui Second People's Hospital manipulated testing procedures and results for children from Heshi Peixin Kindergarten.
The officials placed under 'accountability discipline investigation' include the Communist Party chief for the Gansu health commission, Zhang Hao, and director Liu Borong, provincial disease control bureau director Gan Xiaozhou, Tianshui municipal party committee secretary Feng Wenge and Tianshui mayor Liu Lijiang, the report said.
It also said senior provincial officials were 'deeply saddened' by the poisoning that had shocked the country, and conveyed their sincere apologies to the affected children and their parents
The local government will treat the children free of charge and reimburse any medical costs incurred outside the city, the report added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


South China Morning Post
9 hours ago
- South China Morning Post
Hong Kong students should avoid ordering takeaway food on mainland China trips, authorities say
A new guide has advised students from Hong Kong to refrain from ordering food and drinks through delivery platforms during trips to mainland China in the new academic year, in light of reports that more than 100 students taking part in such tours developed gastroenteritis symptoms. Students were also advised not to go to the gym or use recreational facilities in hotels to ensure they have sufficient rest the following day, according to education authorities. The Education Bureau recently uploaded a document for schools in a 'frequently asked questions' format for such trips in the new academic year.


South China Morning Post
9 hours ago
- South China Morning Post
Chinese man spends US$600,000 at hair salon for detox treatments, feels pain, denied refund
A Chinese man has surprised many by revealing he spent over 4.3 million yuan (US$600,000) at a hair salon over two years on unlicensed detox and wellness treatments – including enemas and acupuncture – which resulted in severe health issues and a denied refund. Advertisement The ordeal began in April 2023, when the man, surnamed Cheng, from Hefei in northern China's Anhui province, met a salon manager, surnamed Chen, at a local hair salon. The manager invited Cheng to the opening of a new branch, where another manager, surnamed Zhou, persuaded him to go upstairs to 'experience a beautician's massage.' It was during this visit that Cheng was pressured into purchasing beauty services in the form of an account top-up. Cheng asserted that during subsequent visits, he faced continual coercion to add more funds to his account. Many netizens were shocked and questioned whether a hair salon is qualified to offer detox treatments, let alone at such high costs. Photo: Shutterstock 'They were all young boys and girls, kneeling and saying they were poor and couldn't even afford rent, relying on customers to help support their parents. Older beauticians nearby would consistently urge customers to top up, stating that the staff earned commissions based on performance,' Cheng recalled.


South China Morning Post
10 hours ago
- South China Morning Post
China approving innovative drugs at record pace as discovery momentum shifts from West
China is making inroads in the race for innovative pharmaceuticals, with a record number of drug approvals this year amid growing appeals for multinational giants to run onshore research entities. Authorities approved 43 innovative drugs in the first half of 2025, marking a 59 per cent year-on-year increase and nearly matching the total of 48 approvals for all of last year, state broadcaster CCTV reported on Wednesday, citing data from the National Medical Products Administration (NMPA). Many of the 43 innovative drugs approved for market launch are for serious conditions such as cancer, metabolic disorders and immune diseases, the report said. 'China's reform of drug review and approval processes has enabled pharmaceutical companies to better forecast their returns on R&D investments … making them more willing to pursue long-term, high-risk innovative drug development,' said Yang Ting, director of the NMPA's drug registration department, in an interview with CCTV. China is the world's second-largest biomedicine market, and global players have been increasingly expanding their presence there. Also in the year's first half, China set a record for licensing out innovative drugs – referring to rights granted to overseas markets – with a total value of US$48.4 billion, according to figures from mainland pharmaceutical consultancy DrugTimes. To further refine manufacturing processes and improve drug quality, additional approval procedures are often required after a drug's market launch.